FDA grants accelerated approval to zanidatamab-hrii
On November 20, 2024, the FDA granted accelerated approval to zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals, Inc.) for biliary tract cancer.
Related Articles
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation
Analysis of 27,810 patients with advanced cancers treated with anti-PD-1/L1 therapies shows that immune gene signatures or immune cell infiltration is not universally associated with…
Energy Transfer and Sunoco donate $2 million to support pediatric cancer research at MD Anderson
The University of Texas MD Anderson Cancer Center today announced a $2 million donation from Dallas-based Energy Transfer as a result of its 2024 workplace…
Plenary Lecture to explore breast cell atlas in cancer prevention, treatment – SABCS Meeting News
Walid Khaled, PhD, will deliver the second plenary lecture during the 2024 San Antonio Breast Cancer Symposium® about cell atlases as roadmaps in cancer immunology.
The American Cancer Society National Lung Cancer Roundtable strategic plan: Promoting guideline‐concordant lung cancer staging
Lung cancer staging is a key determinant of appropriate treatment selection and optimal patient outcomes. This report identifies seven gaps in care delivery and proposes…
Results from a pilot trial evaluating lifileucel in melanoma brain metastases
Allison Betof Warner, MD, Stanford Cancer Center, Stanford, CA, shares results from a pilot trial (NCT05640193) that demonstrated the feasibility of lifileucel for active melanoma…
Welcome! You are invited to join a webinar: SSO & ASTS Virtual Tumor Board: Transplant Oncology . After registering, you will receive a confirmation email about joining the webinar.
Welcome! You are invited to join a webinar: SSO & ASTS Virtual Tumor Board: Transplant Oncology . After registering, you will receive a confirmation email…
How protective antibodies get in malaria’s way
As part of an international collaboration, Fred Hutch scientists provided structural information that helped reveal how two antibodies protect against severe malaria. The findings, published…
Program
Explore the program for the AACR Special Conference in Cancer Research: Translating Targeted Therapies in Combination with Radiotherapy.
Combos Deemed Safe, Effective in Recurrent Glioblastoma
Treatment with retifanlimab, bevacizumab, and hypofractionated radiotherapy — with or without epacadostat — appears safe and effective in patients with recurrent glioblastoma.
OA Virtual conferences
Sorry, your request to load the app is timing out. Please check your internet connection and refresh the page. If the issue continues, try in…
